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Abstract
SARS-CoV-2 is the causative agent behind the COVID-19 pan-
demic, and responsible for tens of millions of infections, and
hundreds of thousands of deaths worldwide. Efforts to test,
treat and vaccinate against this pathogen all benefit from an
improved understanding of the basic biology of SARS-CoV-2.
Both viral and cellular proteases play a crucial role in SARS-
CoV-2 replication, and inhibitors targeting proteases have al-
ready shown success at inhibiting SARS-CoV-2 in cell culture
models. Here, we study proteolytic cleavage of viral and cel-
lular proteins in two cell line models of SARS-CoV-2 replica-
tion using mass spectrometry to identify protein neo-N-termini
generated through protease activity. We identify multiple pre-
viously unknown cleavage sites in multiple viral proteins, in-
cluding major antigenic proteins S and N, which are the main
targets for vaccine and antibody testing efforts. We discovered
significant increases in cellular cleavage events consistent with
cleavage by SARS-CoV-2 main protease, and identify 14 poten-
tial high-confidence substrates of the main and papain-like pro-
teases. We showed that siRNA depletion of these cellular pro-
teins inhibits SARS-CoV-2 replication, and that drugs target-
ing two of these proteins: the tyrosine kinase SRC and Ser/Thr
kinase MYLK, showed a dose-dependent reduction in SARS-
CoV-2 titres. Overall, our study provides a powerful resource to
understand proteolysis in the context of viral infection, and to
inform the development of targeted strategies to inhibit SARS-
CoV-2 and treat COVID-19 disease.
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Introduction
SARS-CoV-2 emerged into the human population in late
2019, as the latest human coronavirus to cause severe dis-
ease following the emergence of SARS-CoV and MERS-
CoV over the preceding decades (1, 2). Efforts to develop
vaccines and therapeutic agents to treat COVID-19 disease
are well underway, however it is widely expected that this
first generation of treatments might provide imperfect pro-
tection from disease. As such, in-depth characterisation of
the virus and its interactions with the host cell can inform
current and next-generation efforts to test, treat and vacci-
nate against SARS-CoV-2. Past efforts in this area have in-
cluded the proteome, phosphoproteome, ubiquitome and in-
teractome of SARS-CoV-2 viral proteins and infected cells
(3–9). Proteolytic cleavage plays a crucial role in the life
cycle of SARS-CoV-2, and indeed most positive-sense RNA
viruses. Inhibitors targeting both viral and cellular proteases
have previously shown the ability to inhibit SARS-CoV-2
replication in cell culture models (10–13). Here we present a
first unbiased study of proteolysis during SARS-CoV-2 infec-
tion, and its implications for viral antigens, as well as cellular
proteins that may represent options for antiviral intervention.
Proteolytic cleavage of the two coronavirus polyproteins gen-
erates the various viral proteins needed to form a replication
complex, required for transcription and replication of the vi-
ral genome and subgenomic mRNAs. The key viral enzymes
responsible are the papain-like (PLP, nsp3) and main pro-
teases (MPro, nsp5). Aside from cleaving viral substrates,
these enzymes can also act on cellular proteins, modifying or
neutralising substrate activity to benefit the virus. A recent
study highlighted the ability of the viral proteases to cleave
proteins involved in innate immune signaling including IRF3,
NLRP12 and TAB1 (14). However, there has yet to be an un-
biased study to identify novel substrates of the coronavirus
proteases in the context of viral infection. The identification
of such substrates can identify cellular enzymes or pathways
required for efficient viral replication that may represent suit-
able targets for pharmaceutical repurposing and antiviral in-
tervention for the treatment of COVID-19 disease.
Viral proteins can also be the targets of cellular proteases,
with the most prominent example for coronaviruses being
the cleavage of the Spike glycoprotein by the cellular pro-
teases furin, TMPRSS2 and Cathepsins (10, 11, 15, 16), but
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the exact cleavage sites within Spike for most of these in-
dividual cellular proteases are not yet characterised. Prote-
olytic processing can also be observed for other coronavirus
proteins, for example, signal peptide cleavage of SARS-CoV
ORF7A (17) and caspase cleavage of the nucleocapsid pro-
tein (18, 19). Many of these viral proteins, and especially the
Spike glycoprotein form part of vaccine candidates currently
undergoing clinical trials. For a functional immune response,
it is vital that the antigens presented to the immune system,
as part of these vaccines, closely mimic those seen in natu-
ral infection. An understanding of any modifications to these
antigens observed during natural infection, such as glycosy-
lation, phosphorylation and proteolytic cleavage, is critical to
enable the rational design and validation of vaccine antigens
and the selection of appropriate systems for their production.
Mass spectrometry-based proteomic approaches have already
led to rapid advances in our understanding of SARS-CoV-2,
with notable examples including the rapid release of the cel-
lular interactome (6) and proximity interactome (7) for a ma-
jority of SARS-CoV-2 proteins, as well as proteomic (3, 5),
phosphoproteomic (4, 8) and ubiquitomic analyses (9) Larger
scale-initiatives have been launched focusing on community
efforts to profile the immune response to infection, and pro-
vide in-depth characterization of viral antigens (20). Mass
spectrometry has particular advantages for investigation of
proteolytic cleavage as analysis can be conducted in an un-
biased manner, and identify not only the substrate, but the
precise site of proteolytic cleavage (21).
In this work we have applied mass spectrometry-based meth-
ods for N-terminomics to study proteolysis and the resulting
proteolytic proteoforms generated in the context of SARS-
CoV-2 infection, enabling the identification of novel cleavage
and processing sites within viral proteins. We also identify
cleavage sites within cellular proteins that match the coro-
navirus protease consensus sequences for Mpro and PLP,
show temporal regulation during infection, and demonstrate
these proteins are required for efficient SARS-CoV-2 repli-
cation. These potential SARS-CoV-2 protease substrates in-
clude proteins that can be targeted with drugs in current clin-
ical use to treat other conditions (22). Indeed, we demon-
strate potent inhibition of SARS-CoV-2 replication with two
compounds that are well-established chemical inhibitors of
the SARS-CoV-2 protease substrates SRC and myosin light
chain kinase (MYLK).
Results
Proteomic analysis of SARS-CoV-2-infected cell lines
identifies alterations to the N-terminome. To investigate
proteolysis during SARS-CoV-2 infection, N-terminomic
analysis at various timepoints during the course of SARS-
CoV-2 infected Vero E6 and A549-Ace2 cells (Fig. 1A)
was performed. Vero E6 cells are an African Green Mon-
key kidney cell line commonly used for the study of a range
of viruses, including SARS-CoV-2 which replicates in this
cell line to high titres. A549-Ace2 cells are a human lung
cell line which has been transduced to overexpress the ACE2
receptor to allow for SARS-CoV-2 entry. Cells were infected
in biological triplicates at a multiplicity of infection (MOI)
of 1, and harvested at 4 timepoints (0, 6, 12 and 24h) post-
infection. Mock-infected samples were collected at 0 and
24h post-infection. These timepoints were chosen to cover
SARS-CoV-2 infection from virus entry, over replication to
virus egress: RNA levels increased from 9h post-infection
(Fig. 1B), protein levels showed steady increases throughout
infection (Fig. 1C), and viral titres increased at the 24h time-
point (Fig. 1D). These features were shared in both cell lines,
with the Vero E6 cells showing greater RNA and protein lev-
els, as well as viral titres compared with the A549-Ace2 cells.
Analysis of the N-termini-enriched samples was performed
by LC-MS/MS following basic reverse phase fractionation.
For the purposes of this analysis, neo-N-termini were taken
to be those beginning at amino acid 2 in a given protein or
later. By this definition these neo-N-termini will include
those with post-translational removal of methionine, signal
peptide cleavage, as well as those cleaved by viral or cellular
proteases. The modified N-terminomic enrichment strategy
used (21) employed isobaric labelling (TMTpro) for quan-
tification as this permitted all samples to be combined prior
to enrichment, minimising sample variability. This strat-
egy meant that only those peptides with a TMTpro-labelled
N-terminus or lysine residue were quantified. As only un-
blocked N-termini are labelled with undecanal, this approach
results in the selective retention of undecanal-tagged tryptic
peptides on C18 in acidified 40% ethanol, with N-terminal
and neo-N-terminal peptides enriched in the unbound frac-
tion (21).
Quality filtering of the dataset was performed (Fig. S1), in-
fected and mock samples separated by PCA and 0h Mock, 0h
infected and 6h infected clustered together, and away from
the 12h and 24h infected samples (Fig. S1A-D). With the
exception of the enriched Vero E6 dataset the 24h mock sam-
ple clustered with the 0h mocks. The Vero E6 24h Mock
clustered away from the 0h and infected samples which may
reflect regulation due to cell confluence as this was not ob-
served with the paired unenriched sample. Sample prepa-
ration successfully enriched for blocked N-termini consist-
ing of acetylated, pyroglutamine-N-termini and TMTpro-
labelled N-termini (Fig. S1), and blocked N-termini were
more abundant in the enriched samples. In both datasets,
TMTpro-labelled N-termini represent approximately 50% of
the blocked N-termini, with the rest split evenly between py-
roglutamine and N-terminal acetylation (Fig. S1). After fil-
tering, over 2700 TMTpro-labelled N-termini representing
neo-N-termini were identified from each cell line.
When the 24h infected and mock-infected timepoints were
compared, both cellular and viral neo-N-termini in A549-
Ace2 cells (Fig. 1) and Vero E6 cells (Fig. 1F) were identified
as showing significant alterations in their abundance. In line
with expectation, N-termini from viral proteins were solely
identified as showing increased abundance during infection in
both cell lines. N-termini from cellular proteins showed both
increased and decreased abundance during infection. We rea-
soned that those neo-N-termini showing increased abundance
would include viral neo-N-termini, as well as those cellular
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Fig. 1. N-terminomic analysis of SARS-CoV-2 infection of A549-Ace2 and Vero E6 cells. A) Experimental design. B) Viral RNA levels were determined by qRT-PCR. C)
Protein levels were determined based on the TMTpro fractional intensity of the total protein intensity for the unenriched proteomic samples. D) Infectious virus production
(PFU). E) A549-Ace2 and F) Vero E6 neo-N-terminomic analysis reveals significant increases in peptides corresponding to viral and cellular neo-N-termini, where neo-N-
termini must begin from amino acid 2 or later. Error bars represent standard deviation, P-values were obtained by t-test, correction for multiple hypothesis testing to obtain
Q-values was performed as described Storey (2002)(23)
proteins cleaved by the SARS-CoV-2 PLP and Mpro pro-
teases. For this study we therefore focused specifically on
viral N-termini and those cellular neo-N-termini identified as
showing significantly increased abundance (t-test, multiple
hypothesis testing corrected Q value ≤ 0.05) during infec-
tion.
Novel proteolytic processing of SARS-CoV-2 proteins
is observed during infection. The 30kb SARS-CoV-2
genome encodes a large number of proteins including two
long polyproteins formed through ribosomal frameshifting,
the structural proteins S, E, M and N and a range of accessory
proteins (Fig. 2). Coronavirus proteins, in line with those of
other positive-sense RNA viruses are known to undergo post-
translational modifications, including proteolytic cleavage in
some cases. Across all datasets we identified the S, M and N
structural proteins, with the exception of E which has also not
been observed in other proteomics datasets due to both short
length and sequence composition (3, 5). We identified the
ORF3a, ORF6, ORF8 and ORF9b accessory proteins, and all
domains of the polyprotein aside from nsp6, 7 and 11.
We first sought to characterise neo-N-termini from viral pro-
teins to understand potential patterns of cleavage that might
generate functional proteolytic protoforms of the viral pro-
teins. Neo- and N-termini were identified from 8 viral pro-
teins including the polyprotein (Fig. 2B-D; Fig. S2). Of these
the nucleocapsid (N), ORF3a accessory protein and Spike
were most prominent. More cleavage sites were observed
from infected Vero E6 cells than A549-Ace2 cells, which is in
line with expectation given the higher levels of viral protein
expression, and superior infectivity of this cell line compared
to the A549-Ace2 cell line.
The coronavirus N protein is highly expressed during infec-
tion, and also represents a major antigen detected by the host
immune response. Prior studies have identified cleavage of
the SARS-CoV N protein by cellular proteases (18, 19), and
our data identified multiple neo-N-termini consistent with
proteolytic cleavage from both infected A549-Ace2 and Vero
E6 cells (Fig. 2B). neo-N-termini common to both datasets
include amino acids 17, 19, 69, 71, 76, 78, 154, and 263.
Many of these cleavage sites were spaced closely together
(e.g. 17/19, 69/71), consistent with a degree of further endo-
proteolytic processing.
The ORF3a putative viroporin also shows N-terminal pro-
cessing, possibly reflecting signal peptide cleavage (Fig. 2C).
In a recent study, cryoEM of ORF3a in lipid nanodiscs did
not resolve the first 39 N-terminal suggesting this region is
unstructured (24). We observed N-terminal processing sites
in the first 22 residues of the protein, with neo-N-termini
beginning at amino acids, 10, 13 and 16 identified in both
datasets, giving a possible explanation for the lack of N-
terminal amino acids in cryoEM experiments.
Proteolytic cleavage of the Spike glycoprotein is of major in-
terest as it can play an important role in cell entry, with dif-
ferent distributions of cellular proteases between cell types
resulting in the usage of different entry pathways, as well as
potentially changing availability of surface epitopes for an-
tibody recognition. Key proteases include furin, TMPRSS2
and cathepsins, though in the latter two cases the actual cleav-
age sites targeted by these enzymes to process Spike into
S1 and S2 remain unclear. Consistent with previous obser-
vations (3, 5), we do not detect a neo-N-terminus deriving
from the furin cleavage site as the trypsin digestion we em-
ployed would not be expected to yield peptides of suitable
length for analysis. However, while beneficial for replica-
tion, furin cleavage is not essential and other cleavage events
within Spike can compensate (15, 16). We detect neo-N-
terminal peptides from S637 in both datasets (Fig. 2D). In
line with the pattern of viral gene expression observed in the
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unenriched datasets this neo-N-terminus showed consistent
increases in abundance throughout the experimental time-
course (Fig. 2E). S637 is located on a flexible loop near the
furin cleavage site (Fig. 2F), suggesting it is accessible for
protease cleavage (25). A mass spectrum for the S637 neo-
N-terminus from the A549-Ace2 dataset is shown in Fig. 2G,
the same peptide was observed with both 2+ and 3+ charge
states in the Vero E6 dataset, and with a higher Andromeda
score (124.37 vs. 104.82). Intriguing, S637 was identified as
a phosphorylation site in Davidson et al. (3). As phospho-
rylation can inhibit proteolytic cleavage when close the the
cleavage site, this suggests potential post-translational regu-
lation of this cleavage event.
Further neo-N-termini from Spike were identified in the Vero
E6 dataset alone, including a neo-N-terminus beginning at
Q14. This is slightly C-terminal of the predicted signal pep-
tide which covers the first 12 amino acids. This peptide fea-
tured N-terminal pyroglutamic acid formed by cyclization of
the N-terminal glutamine residue. The peptide does not fol-
low an R or K residue in the Spike amino acid sequence and
thus represents non-tryptic cleavage. The absence of TMT-
pro labelling at the N-terminus suggests that this N-terminus
was blocked prior to tryptic digestion, with this modified N-
terminus preventing TMTpro modification. Artifactual cy-
clization of N-terminal glutamine or glutamic acid residues
typically results from extended trypsin digestion and acidic
conditions (26). However, the order of labelling and diges-
tion steps in our protocol, and non-tryptic nature of this pep-
tide suggests that this N-terminal pyroglutamic acid residue
is an accurate reflection of the state of this neo-N-terminus
in the original biological sample. Three further N-terminal
pyroglutamic acid residues were identified in SARS-CoV-2
proteins within the Vero E6 dataset and can be found in table
S2.
We detected viral neo-N-termini and N-termini in M, ORF7a,
ORF9b and pp1ab. Due to conservation with SARS-CoV
ORF7a, the first 15 residues of SARS-CoV-2 ORF7a are
expected to function as a signal peptide which is post-
translationally cleaved (17, 27). neo-N-termini were iden-
tified in both datasets consistent with this hypothesis. Due
to inclusion of the ORF7a iORF1 proposed N-terminal trun-
cation of ORF7a which lacks the first two amino acids in
ORF7a in the SARS-CoV-2 sequences used for data analy-
sis, the start position of this neo-N-terminal peptide is given
as 14 (28). However, this would be position 16 in ORF7a,
consistent with removal of the signal peptide (MKIILFLAL-
ITLATC , in Uniprot P0DTC7), and conserved with that in
SARS-CoV ORF7a.
The native N-terminus of ORF9b was also identified, and sev-
eral sites mapping to the replicase polyprotein, including a
conserved neo-N-terminus consistent with predicted nsp10-
nsp12 cleavage by Mpro. A neo-N-terminus consistent with
nsp15-nsp16 cleavage by Mpro was identified in A549-Ace2
cells, and several internal neo-N-termini deriving from nsp1,
-2 and -3 were also observed, though not common to both
datasets. All the viral neo-N-termini and N-termini identi-
fied in this study can be found in tables S1 (A549-Ace2) and
S2 (Vero E6) respectively. Table S3 includes all viral pep-
tides identified in this study in both enriched and unenriched
datasets.
SARS-CoV-2 infection induces proteolytic cleavage of
multiple host proteins. The consensus sequences for coro-
navirus proteases are conserved between coronaviruses, with
PLP recognising a P4 to P1 LxGG motif, and Mpro recog-
nising a (A|P|S|T|V)xLQ motif (29). No strong preference
has been identified for either protease at the P3 residue (Fig.
3A). Analysis of both datasets showed strong enrichment for
neo-N-termini consistent with cleavage at Mpro motifs (two-
tailed Kolmogorov-Smirnov test, p<0.001, Fig. 3B,C). How-
ever, no comparable enrichment could be seen for neo-N-
termini consistent with cleavage at PLP motifs (Fig. 3D,E).
This may reflect fewer cellular protein substrates of PLP
compared to Mpro, or higher background levels of neo-N-
termini generated by cellular proteases with similar P4 to P1
cleavage specificities as PLP.
Neo-N-termini matching, or close to the consensus se-
quences, for either Mpro or PLP and showing significant
upregulation (t-test, q ≤ 0.05 after correction for multiple
hypothesis testing) at 24h post-infection compared to the
24h mock sample were selected for further analysis. Per-
fect matches to the consensus sequences from A549-Ace2
cells included NUP107, PAICS, PNN, SRC and XRCC1.
GOLGA3 and MYLK (MCLK) were identified from Vero
E6 cells. Hits from both cell lines that resembled, but
did not completely match the consensus sequence were
ATAD2, ATP5F1B, BST1, KAT7, KLHDC10, NUCKS1 and
WNK1 (Fig. 3F, G). Adding confidence to these obser-
vations, approximately half of these hits were also iden-
tified in a recent SARS-CoV-2 proximity labelling study
(ATP5F1B, GOLGA3, NUP107, PNN, SRC and WNK)(7),
and GOLGA3 was additionally identified in an interactome
study as an nsp13 interaction partner (6).
SRC, MYLK and WNK are all protein kinases, one of the
protein families best studied as drug targets (30). MYLK is
especially interesting as dysregulation of MYLK has been
linked to acute respiratory distress syndrome - one of the
symptoms of severe COVID-19 disease (31). NUP107
is a member of the nuclear pore complex, with nucleo-
cytoplasmic transport a frequent target for viral disregulation
(32). GOLGA3 is thought to play a role in localisation of the
Golgi and Golgi-nuclear interactions, and was identified in
two recent studies of SARS-CoV-2 interactions (6, 7). PNN
is a transcriptional activator, forming part of the exon junc-
tion complex, with roles in splicing and nonsense-mediated
decay. The coronavirus mouse hepatitis virus has previously
been shown to target nonsense mediated decay, with pro-viral
effects of inhibition (33). PAICS and BST1 both encode en-
zymes with roles in ADP ribose and purine metabolism re-
spectively, with PAICS previously identified as binding the
influenza virus nucleoprotein (34).
The majority of these neo-N-termini showed enrichment at
24h, with levels remaining largely unchanged at earlier time-
points, especially for Mpro substrates (Fig. 3F,G). This
matches the timing for peak viral RNA, protein expression
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Fig. 2. Proteolysis of viral proteins during SARS-CoV-2 infection. A) Schematic of the SARS-CoV-2 genome and proteome, with the nsp3 (PLP) and nsp3 (MPro) highlighted.
Proteolytic processing of SARS-CoV-2 proteins during infection of A549-Ace2 and Vero E6 cells includes B) extensive cleavage of the nucleocapsid protein C) N-terminal
processing of the ORF3a putative viroporin, and D) a novel cleavage site between Y636 and S637 in Spike, N-terminal of the furin cleavage site. E) The abundance of the
S637 spike neo-N-terminus increases over the infection timecourse, F) This cleavage site is present on an flexible region, C-terminal of the RBD (PDB: 6X6P G) A mass
spectrum for the S637 peptide from A549-Ace2 cells is shown.
and titres over the timepoints examined (Fig. 1B-D). Excep-
tions to this trend include the potential PLP substrates, 2/3
of which begin to show increased abundance at 12h post-
infection, with BST1 appearing to peak at 12h rather than
24h, indicating a potential temporal regulation of the two vi-
ral proteases. Data for all quantified and filtered N- and neo-
N-termini from A549-Ace2 and Vero E6 cells is available in
tables S4 and S5 respectively.
Prospective MPro and PLP substrates are necessary
for efficient viral replication, and represent targets for
pharmacological intervention. To investigate if the puta-
tive cellular substrates of MPro and PLP identified in the N-
terminomic analyses are necessary for efficient viral repli-
cation, an siRNA screen was conducted Fig. 4. Where
proteolytic cleavage inactivates cellular proteins or path-
ways inhibitory for SARS-CoV-2 replication, siRNA deple-
tion would be anticipated to result in inreased viral titres
and/or RNA levels. If proteolysis results in altered func-
tion that is beneficial for the virus, we would expect siRNA
depletion to result in a reduction in viral titres/RNA levels.
Proteins with neo-N-termini showing statistically significant
increased abundance during SARS-CoV-2 infection and ei-
ther matching, or similar to the viral protease consensus se-
quences were selected for siRNA depletion.
Infection of A549-Ace2 cells was performed 24h post-
transfection with the indicated siRNA and allowed to pro-
ceed for 72h (Fig. 4A). Cell viability for all targets was
comparable to untreated controls (Fig. S3). siRNA knock-
down efficiency at the time of infection was confirmed by
qRT-PCR (Fig. S4), with a low of 77% efficiency for
NUCKS1, and averaging over 95% efficiency for most tar-
gets.10/14 coronavirus protease substrates showed significant
reductions (one-way ANOVA, p ≤ 0.01) in viral RNA lev-
els, averaging a 100-1000-fold median decrease in viral RNA
equating to pfu equivalents per ml at 72h post-infection com-
pared to treatment with a control siRNA (Fig. 4B). PAICS,
GOLGA3, NUCKS1, and XRCC1 did not show a signifi-
cant drop in RNA copy number following siRNA treatment.
Plaque assays were then conducted on these samples to de-
termine whether this observed reduction in viral RNA lev-
els reflected a reduction in infectious virus titres (Fig. 4C).
All 14 potential substrates showed a statistically significant
(one-way ANOVA, p ≤ 0.01) reduction in viral titres follow-
ing siRNA depletion. For PAICS and GOLGA3, which did
not show reduced RNA levels, these reductions were approx-
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Vero E6 cellular neo-N-termini
A549-Ace2: (A|P|S|T|V)xLQ enrichment A549-Ace2: LxGG enrichment
Vero E6: (A|P|S|T|V)xLQ enrichment Vero E6: LxGG enrichment
Fig. 3. Increased abundance of novel cellular neo-N-termini consistent with SARS-CoV-2 protease consensus sequences suggests viral protease activity on cellular
substrates. a) Consensus motifs for Mpro and PLP. b) and c) Distribution of neo-N-termini consistent with the Mpro consensus motif in A549-Ace2 and Vero E6 cells
respectively. d) and e) Distribution of neo-N-termini consistent with the PLP consensus motif in A549-Ace2 and Vero E6 cells respectively. Distributions cover all three
biological replicates. Enrichment was determined by two-tailed Kolmogorov-Smirnov test. f) and g) show the relative abundance of cellular neo-N-termini identified as
significantly upregulated (t-test, multiple-hypothesis corrected q <= 0.05) and matching or resembling the Mpro or PLP consensus motifs from A549-Ace2 or Vero E6 cells
respectively. Sequence match to the consensus is indicated by the pink or green coloring of the P4 to P1 positions of the relevant cleavage sites indicating match to the Mpro
or PLP P4, P2 or P1 positions respectively.
imately 10-fold. Most other siRNA targets showed reduced
titres in the 100-1000-fold range. These differences in out-
come between viral RNA levels and plaque assays may result
from a subset of proteins required for efficient viral replica-
tion. While efficient mRNA knockdown was shown for all
targets Fig. S4, it is also possible that this discrepancy be-
tween viral RNA levels and titres may result from differences
in protein half-life of the knockdown targets. This could re-
sult in proteins with longer half lives only giving a phenotype
at later stages of infection when infectious virus is produced.
A subset of the prospective viral protease substrates have
commercially-available inhibitors, notably SRC and MYLK.
In the case of SRC these include tyrosine kinase inhibitors
in current clinical use. In light of the siRNA screening re-
sults we concluded that pharmacological inhibition of SARS-
CoV-2 protease substrates could represent a viable means to
inhibit SARS-CoV-2 infection. Dose-response experiments
were conducted with 7 inhibitors to determine whether phar-
macological inhibition of SARS-CoV-2 protease substrates
could be employed as a potential therapeutic strategy (Fig. 5;
Fig. S5). Of these, two tyrosine kinase inhibitors: Bafetinib
and Sorafenib showed inhibition at concentrations which did
not result in cytotoxicity in the human cell line A549-Ace2
(Fig. 5). In the case of Bafetinib, a Lyn/Bcr-Abl inhibitor
which has off-target activity against SRC the IC50 was in
the nanomolar range (IC50: 0.79 µM, 95% confidence in-
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A549-Ace2 Vero E6 Imperfect Match
Fig. 4. siRNA depletion of potential MPro and PLP substrates results in signifi-
cant reductions to viral RNA copies and titres in A549-Ace2 cells. A) Experimental
design, B) Viral RNA copies and C) titres in supernatant at 72h post-infection, fol-
lowing infection 24h post-transfection with the indicated siRNA. Colored bars indi-
cate median (hollow circle) and 25th and 75th percentiles. Individual datapoints are
shown in grey. Significance was calculated by one-way ANOVA. Blue bars indicate
samples with significantly reduced viral RNA copies or titres (p<=0.01). Those not
meeting this threshold are shown in red. The control siRNA-treated sample is indi-
cated with a black bar. The limit of detection in the plaque assay was calculated to
be 40 PFU/mL (dotted line).
terval 0.23-1.35 µM). Bafetinib has recently been indepen-
dently identified as an inhibitor of the coronaviruses OC43
and SARS-COV-2 in a large-scale drug-repurposing screen
(35). Inhibition with Sorafenib which was included as a pos-
itive control and does not directly target any of the protease
substrates was in the low micromolar range (Fig. 5), in line
with a previously published report (4). Two inhibitors were
trialed against MYLK. These were MLCK inhibitor peptide
18, and ML-7. Only ML-7 showed inhibition of SARS-CoV-
2, with inhibition in the low micromolar range (IC50: 1.7
µM, 95% confidence interval 1.51-1.80 µM), at concentra-
tions which did not induce cytotoxicity (Fig. 5; Fig. S6).
ML-7 and MLCK inhibitor peptide 18 have different mecha-
nisms of action, with MLCK inhibitor peptide 18 outcompet-
ing kinase substrate peptides, and ML-7 inhibiting ATPase
activity. All four had CC50 values over the 10µM maximum
Fig. 5. Inhibitors targeting viral protease substrates reduce SARS-CoV-2 titres
in A549-Ace2 cells. Sorafenib is a tyrosine kinase inhibitor previously shown to
inhibit SARS-CoV-2 replication (4). Bafetinib is a tyrosine kinase inhibitor with off-
target activity against SRC kinase. ML-7 and MLCK target myosin light chain kinase
(MYLK/MLCK). Error bars represent standard deviation from 3 biological replicates.
Red circles indicate individual datapoints..
concentration tested, except ML-7 which had a CC50 of 5
µM. Bafetinib did show reduced viability at the two highest
concentrations tested (10 µM, 3.3 µM), though not reaching
50% reduction (Fig. S6).
The other 3 tyrosine kinase inhibitors tested (Bosutinib, Sara-
catinib, Dasatinib) all showed inhibition Fig. S5, however cy-
totoxicity results obtained with the assay used were also high
preventing the unambiguous determination of whether inhi-
bition was specific or due to cytotoxicity Fig. S6. However,
it should be noted that these agents have been reported to be
cytostatic in A549 cells, and the CellTiter Gloassay used to
assess viability measures cellular metabolism so will not dis-
tinguish between cytostatic and cytotoxic effects.
Discussion
We employed a mass spectrometry approach to study pro-
teolytic cleavage events during SARS-CoV-2 infection. Sub-
strates of viral proteases are frequently inferred through stud-
ies of related proteases (36). However, such approaches
are unable to identify novel substrates, and even closely-
related proteases can differ in their substrate specificity (37).
Mass spectrometry-based approaches to identify protease
substrates by identifying the neo-N-terminal peptides gener-
ated by protease activity have existed for a number of years
(21, 38–40), however, they have seen only limited application
to the study of viral substrates (41), and have not been previ-
ously applied to the study of proteolysis during coronavirus
infection.
While our approach identified multiple novel viral and cel-
lular cleavage sites, it also failed to identify multiple known
cleavage sites, including the furin cleavage site in Spike, and
multiple cleavage sites within the viral polyprotein. This can
be understood from the dependence of the approach on the
specific protease used for mass spectrometry analysis. Iso-
baric labelling prior to trypsin digestion blocks tryptic cleav-
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age at lysine residues and causes trypsin to cleave solely af-
ter arginine residues. This results in the generation of long
peptides and if the specific cleavage site does not produce a
peptide of suitable length for analysis (typically 8-30 amino
acids) then it will be missed. This can be alleviated through
the application of multiple mass spectrometry-compatible
proteases in parallel, yielding multiple peptides of different
length for each cleavage site (42, 43). This would both in-
crease the number of sites identified and cross-validate pre-
viously identified cleavage sites. These methods will likely
prove a fruitful avenue for future investigations of proteoly-
sis during infection with SARS-CoV-2 and other viruses that
employ protease-driven mechanisms of viral replication.
Our approach identified multiple cleavage sites within viral
proteins. In some cases, such as the nucleocapsid protein,
cleavage by cellular proteases has been observed for SARS-
CoV (18, 19), though the number of cleavage products ob-
served was much higher in our study (Fig. 2). Compared
to the gel-based approaches used in the past, our approach
is much more sensitive for detecting when protease activity
results in N-termini with ragged ends, due to further endo-
proteolytic activity. Examples of this in our data are particu-
larly evident in Fig. 2 for the nucleocapsid and ORF3a where
neo-N-termini appear in clusters. Cleavage sites within the
nucleocapsid and Spike protein are of particular interest as
these are the two viral antigens to which research is closely
focuses for both testing and vaccination purposes. In this
context, neo-N-termini are of interest as N-termini can be
recognised by the immune response, as they are typically
surface-exposed. Antibodies recognising neo-N-termini such
sites will not be detected in tests using complete or recombi-
nant fragments that do not account for such cleavage sites.
Understanding cleavage events can also inform interpretation
of protein structural analysis, for example in the ORF3a vi-
roporin (24). Knowledge of cleavage sites can permit further
analysis of Spike entry mechanisms, and vaccine design, es-
pecially when considering N-terminal modifications such as
pyroglutamine which will impact antibody binding in this re-
gion.
Proteolytic cleavage can alter protein function in several
ways, including inactivation, re-localisation, or altered func-
tion including the removal of inhibitory domains. Our siRNA
screen showed knockdown of the majority of potential pro-
tease targets we identified was inhibitory to SARS-CoV-2
replication (Fig. 4). Indeed, no siRNA treatment resulted in
higher viral titres or RNA levels, suggesting that inactivation
is not the prime purpose of these cleavage events. This sug-
gests that in many cases, proteolytic cleavage by viral pro-
teases may be extremely targeted, serving to fine-tune pro-
tein activity, rather than merely serving as a blunt instrument
to shut down unfavorable host responses. An improved un-
derstanding of the exact ways in which proteolytic cleavage
modulates protein activity and serves to benefit viral replica-
tion will be crucial for targeting cellular substrates of viral
proteases as a therapeutic strategy.
Limitations
In this study, we used two cell line models to characterise
the effects of SARS-CoV-2 infection on protease activity and
the generation of viral and cellular cleavage products. No-
tably, we tested the efficiency of several inhibitors against
SARS-CoV-2 infection only in the context of the A549-
Ace2 cell line model. These results present preliminary data
that must be further validated in other models, in vivo, and
through clinical trials before use in patients for the treatment
of COVID-19 disease.
Materials & Methods
Cell culture Virus. Vero E6 (Vero 76, clone E6, Vero
E6, ATCC® CRL-1586TM) authenticated by ATCC and
tested negative for mycoplasma contamination prior to com-
mencement were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM; Thermo Fisher Scientific) contain-
ing 10% (v/v) fetal bovine serum (FBS, ThermoFisher
Scientific) and penicillin/streptavidin (ThermoFisher Scien-
tific). A549-Ace2 cells, a human lung epithelial cell line
that over-expresses ACE2, were kindly provided by Oliver
Schwartz (Institut Pasteur) (44). A549-Ace2 cells were
cultured in DMEM supplemented with 10% FBS, peni-
cillin/streptavidin and 10 µg/ml blasticidin (Sigma) and
maintained at 37°C with 5% CO2. The SARS-CoV-2 iso-
late BetaCoV/France/IDF0372/2020 was supplied through
the European Virus Archive goes Global (EVAg) platform.
Viral stocks were prepared by propagation in Vero E6 cells in
DMEM supplemented with 2% FBS. All experiments involv-
ing live SARS-CoV-2 were performed in compliance with In-
stitut Pasteur Paris’s guidelines for Biosafety Level 3 (BSL-3)
containment procedures in approved laboratories. All exper-
iments were performed in at least three biologically indepen-
dent samples.
SARS-CoV-2 titration by plaque assay. Vero E6 cells
were seeded in 24-well plates at a concentration of 7.5x104
cells/well. The following day, serial dilutions were per-
formed in serum-free MEM media. After 1 hour absorp-
tion at 37°C, 2x overlay media was added to the inoculum to
give a final concentration of 2% (v/v) FBS / MEM media and
0.4% (w/v) SeaPrep Agarose (Lonza) to achieve a semi-solid
overlay. Plaque assays were incubated at 37° C for 3 days.
Samples were fixed using 4% Formalin (Sigma Aldrich) and
plaques were visualized using crystal Violet solution (Sigma
Aldrich).
Infections for N-terminomic/proteomic analysis. N-
terminomic sample preparation is based around Weng et al.
2019 Mol. Cell. Proteomics, adapted for TMTpro-based
quantitation (21, 45). Vero E6 or A549-Ace2 cells were
seeded using 2x106 cells in T25 flasks. The following day
cells were either mock infected or infected with SARS-CoV-
2 at a MOI of 1 in serum-free DMEM at 37°C for 1 hour.
After absorption, the 0 hour samples were lysed immediately,
while the media for other samples was replaced with 2% FBS
/ DMEM (ThermoFisher Scientific) and incubated at 37°C
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for times indicated before lysis. Cells were washed 3x with
PBS (ThermoFisher Scientific) before lysing them in 100
mM HEPES pH 7.4 (ThermoFisher Scientific), 1% Igepal
(Sigma Aldrich), 1% sodium dodecyl sulfate (SDS; Ther-
moFisher Scientific), and protease inhibitor (mini-cOmplete,
Roche). Samples were then heated to 95°C for 5 minutes,
before immediately freezing at -80°C. Samples were then
thawed and incubated with benzonase for 30 min at 37°C.
Sample concentrations were normalized by BCA assay, and
25µg of material from each sample was used for downstream
processing.
DTT was added to 10mM and incubated at 37°C for 30 min,
before alkylation with 50mM 2-chloroacetamide at room
temperature in the dark for 30 min. DTT at 50mM final
concentration was added to quench the 2-chloroacetamide for
20 min at room temperature. Samples were washed by SP3-
based precipitation (REF). Each sample was resuspended in
22.5µL 6M GuCl, 30µL of 0.5M HEPES pH8, and 4.5µL
TCEP (10mM final) and incubated for 30 minutes at room
temperature.
0.5mg of individual TMTpro aliquots (Lot VB294905) were
resuspended in 62uL of anhydrous DMSO. 57µL of the TMT-
pro was then added to each sample, mixed and incubated
for 1.5h. Label allocation was randomized using the Mat-
lab Randperm function. Excess TMTpro was quenched with
the addition of 13µL of 1M ethanolamide and incubated for
45 min. All samples were combined for downstream process-
ing. SP3 cleanup was performed on the combined samples.
These were resuspended in 400µL of 200mM HEPES pH8,
containing Trypsin gold at a concentration of 25ng/µL and
incubated overnight at 37°C.
Samples were placed on a magnetic rack for 5 min. 10% of
the samples was retained for the unenriched analysis. The
remaining material was supplemented with 100% ethanol to
a final concentration of 40%, undecanal added at an unde-
canal:peptide ratio of 20:1 and sodium cyanoborohydride to
30mM. pH was confirmed to be between pH7-8 and the sam-
ples were incubated at 37°C for 1h. Samples were then son-
icated for 15 seconds, and bound to a magnetic stand for 1
min. The supernatant was retained and then acidified with
5% TFA in 40% ethanol. Macrospin columns (Nest group)
were equilibrated in 0.1% TFA in 40% ethanol. The acidi-
fied sample was applied to the column, and the flow through
retained as the N-terminal-enriched sample.
Both unenriched and enriched samples were desalted on
macrospin columns (Nest group), before drying down again.
Off-line basic reverse phase fractionation for both unenriched
and enriched samples was performed on a Waters nanoAc-
quity with an Acquity UPLC M-Class CSH C18 130A 1.7µm,
300µm x 150µm column. The sample was run on a 70 minute
gradient at 6µL/min flow rate. Gradient parameters were 10
min 3% B, 10-40 min 3-34% B, 40-45 min 34-45% B, 45-50
min 45-99%B, 50-60 min 99% B, 60.1-70 min 3% B. Buffers
A and B were 10mM ammonium formate pH10, and 10mM
ammonium formate pH10 in 90% acetonitrile respectively.
Both samples were resuspended in buffer A, and 1 minute
fractions were collected for 1-65 min of the run. These were
concatenated into 12 (1:13:24. . . ) or 5 fractions (1:6:11. . . )
for unenriched and enriched samples respectively using a
SunChrom Micro Fraction Collector. Samples were dried
down and resuspended in 1% formic acid for LC-MS/MS
analysis.
Mass spectrometry. LC-MS/MS analysis was conducted
on a Dionex 3000 coupled in-line to a Q-Exactive-HF mass
spectrometer. Digests were loaded onto a trap column (Ac-
claim PepMap 100, 2 cm x 75 microM inner diameter, C18,
3 microM, 100 Å) at 5 µL per min in 0.1%(v/v) TFA and
2%(v/v) acetonitrile. After 3 min, the trap column was set in-
line with an analytical column (Easy-Spray PepMap® RSLC
15 cm x 50cm inner diameter, C18, 2 microlM, 100 Å)
(Dionex). Peptides were loaded in 0.1%(v/v) formic acid
and eluted with a linear gradient of 3.8–50% buffer B (HPLC
grade acetonitrile 80%(v/v) with 0.1%(v/v) formic acid) over
95 min at 300 nl per min, followed by a washing step (5 min
at 99% solvent B) and an equilibration step (25 min at 3.8%
solvent). All peptide separations were carried out using an
Ultimate 3000 nano system (Dionex/Thermo Fisher Scien-
tific).. The Q-Exactive-HF was operated in data-dependent
mode with survey scans aquired at a resolution of 60,000 at
200m/z over a scan range of 350-2000m/z. The top 16 most
abundant ions with charge states +2 to +5 from the survey
scan were selected for MS2 analysis at 60,000 m/z resolution
with an isolation window of 0.7m/z, with a (N)CE of 30. The
maximum injection times were 100ms and 90ms for MS1 and
MS2 respectively, and AGC targets were 3e6 and 1e5 respec-
tively. Dynamic exclusion (20 seconds) was enabled.
Data analysis. All data were analysed using Maxquant ver-
sion 1.6.7.0 (46). Custom modifications were generated to
permit analysis of TMTpro 16plex-labelled samples. FASTA
files corresponding to the reviewed Human proteome (20,350
entries, downloaded 8th May 2020), and African Green mon-
key proteome (Chlorocebus sabeus, 19,223 entries, down-
loaded 16th May 2020). A custom fasta file for SARS-CoV-2
was generated from the Uniprot-reviewed SARS-CoV-2 pro-
tein sequences (2697049). This file was modified to addi-
tionally include the processed products of pp1a and pp1b,
novel coding products identified by ribo-seq (28), as well as
incorporate two coding changes identified during sequenc-
ing (Spike: V367F, ORF3a: G251V). All FASTA files, TMT
randomisation strategy, and the modifications.xml file con-
taining TMTpro modifications have been included with the
mass spectrometry data depositions. Annotated spectra cov-
ering peptide N-termini of interest were prepared using xiS-
PEC v2(47).
Several different sets of search parameters were used for
analysis of different experiments.
For analysis of unenriched material from fractionated
lysates. Default MaxQuant settings were used with the fol-
lowing alterations. As the experimental design meant un-
enriched samples contained a majority of peptides lacking
N-terminal TMT labelling, quantification was performed at
MS2-level with the correction factors from Lot VB294905
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on lysine labelling only with the N-Terminal label left un-
used. Digestion was trypsin/p with a maximum of 3 missed
cleavages. Carbamidomethylation of cysteines was selected
as a fixed modification. Oxidation (M), Acetylation (Protein
N-terminus), and N-terminal TMTpro labelling were selected
as variable modifications. PSM and Protein FDR were set at
0.01.
For analysis of fractionated, N-terminally-enriched material.
Default MaxQuant settings were used with the following al-
terations. Quantification was performed at MS2-level with
the correction factors from Lot VB294905. Digestion was
semi-specific ArgC, as TMTpro labelling of lysines blocks
trypsin-cleavage. Carbamidomethylation of cysteines was
selected as a fixed modification. Oxidation (M), Acetyla-
tion (Protein N-terminus), Gln/Glu to pyroglutamine were se-
lected as variable modifications. PSM and Protein FDR were
set at 0.01.
For analysis of viral protein neo-N-termini from fractionated,
N-terminally-enriched material. Default MaxQuant settings
were used with the following alterations. MS1-based quan-
titation was selected. Digestion was ArgC, sei-specific N-
terminus. Carbamidomethylation of cysteines was selected
as a fixed modification. Oxidation (M), Acetylation (Protein
N-terminus), Gln/Glu to pyroglutamine, and TMTpro mod-
ification of N-termini and lysine residues were selected as
variable modifications. PSM and Protein FDR were set at
0.01.
All downstream analysis was conducted in Matlab. Reverse
hits and contaminants were removed, peptides were filtered
to meet PEP ≤ 0.02. For quantitative analysis, peptides were
further filtered at PIF ≥ 0.7. TMTpro data was normalised
for differences in protein loading by dividing by the label
median, rows were filtered to remove rows with more than
2/3 missing data. Missing data was KNN imputed, and in-
dividual peptides were normalised by dividing by their mean
abundance accross all TMTpro channels. As the objective
was to identify protein cleavage events, peptides were fur-
ther filtered to remove those beginning at the first or second
amino acid in a protein sequence that represent the native N-
terminus. +/- methionine. neo-N-termini were annotated if
they matched known signal peptides. For non-quantitative
analysis (e.g. mapping of viral neo-N-termini), peptides were
filtered to retain only blocked (acetylated, TMTpro labelled,
and pyroglutamine) N-termini. Pyroglutamine-blocked N-
termini were discarded if they were preceeded by arginine or
lysine as these could represent artifactual cyclization of tryp-
tic N-termini. Fractional protein or peptide intensity was cal-
culated as the total intensity for the protein or peptide, mul-
tiplied by the fraction of the summed normalised TMTpro
intensity represented by a particular TMTpro label of inter-
est.
Visualisation of the Y636/S637 cleavage site within the
SARS-CoV-2 Spike glycoprotein structure was performed
using PDB: 6X6P (25), in UCSF ChimeraX v1.0 (48).
Virus infections in siRNA-based cellular protein
knockdowns . Host proteins were knocked-down in A549-
Ace2 cells using specific dsiRNAs from IDT. Briefly, A549-
Ace2 cells seeded at 1x104 cells/well in 96-well plates. Af-
ter 24 hours, each well was transfected with 5 pmol of indi-
vidual dsiRNAs using Lipofectamine RNAiMAX (Thermo
Fisher Scientific) according to the manufacturer’s instruc-
tions. 24 hours post transfection, the cell culture super-
natant was removed and replaced with virus inoculum (MOI
of 0.1 PFU/cell). Following a 1 hour adsorption at 37°C,
the virus inoculum was removed and replaced with fresh 2%
FBS/DMEM media. Cells were incubated at 37°C for 3
days before supernatants were harvested. Samples were ei-
ther heat-inactivated at 80°C for 20 min and viral RNA was
quantified by RT-qPCR, using previously published SARS-
CoV-2 specific primers targeting the N gene (49). RT-qPCR
was performed using the Luna Universal One-Step RT-qPCR
Kit (NEB) in an Applied Biosystems QuantStudio 7 thermo-
cycler, using the following cycling conditions: 55 °C for 10
min, 95 °C for 1 min, and 40 cycles of 95 °C for 10 sec, fol-
lowed by 60 °C for 1 min. The quantity of viral genomes
is expressed as PFU equivalents, and was calculated by per-
forming a standard curve with RNA derived from a viral
stock with a known viral titer. Alternatively, infectious virus
titers were quantified using plaque assays as described above.
To quantify siRNA-based cellular protein knockdowns,
A549-Ace2 cells were seeded and transfected with individ-
ual dsiRNAs as described above. After 24 hours incuba-
tion at 37 °C cells were lysed and RNA was extracted us-
ing Trizol (ThermoFisher Scientific) followed by purifica-
tion using the Direct-zol-96 RNA extraction kit (Zymo) fol-
lowing the manufacturer’s instructions. RNA levels of tar-
get proteins were subsequently quantified by using RT-with
the Luna Universal One-Step RT-qPCR Kit (NEB) in an Ap-
plied Biosystems QuantStudio 7 thermocycler using gene-
specific primers. Expression levels were compared to scram-
bled dsiRNA-transfected cells und normalized to expression
of human beta-actin. Knockdown efficiencies were calcu-
lated usingΔΔCt in Matlab.
To assess cell viability after siRNA knockdowns, cells were
seeded and transfected as described above. 24 hours af-
ter transfection cell viability was measured using alamar-
Blue reagent (ThermoFisher Scientific), media was removed
and replaced with alamarBlue and incubated for 1h at 37
°C and fluorescence measured in a Tecan Infinite M200 Pro
plate reader. Percentage viability was calculated relative to
untreated cells (100% viability) and cells lysed with 20%
ethanol (0% viability), included in each plate.
Drug Screens and Cytotoxicity analysis. Black with
clear bottom 384 well plates were seeded with 2x103 A549-
Ace2 cells per well. The following day, individual com-
pounds were added using the Echo 550 acoustic dispenser at
concentrations indicated 2 hours prior to infection. DMSO-
only (0.5%) and remdesivir (10µM; SelleckChem) controls
were added in each plate. After the pre-incubation period,
the drug-containing media was removed, and replaced with
virus inoculum (MOI of 0.1 PFU/cell). Following a one-
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hour adsorption at 37°C, the virus inoculum was removed
and replaced with 2% FBS/DMEM media containing the in-
dividual drugs at the indicated concentrations. Cells were
incubated at 37°C for 3 days. Supernatants were harvested
and heat-inactivated at 80°C for 20 min. Detection of viral
genomes from heat-inactivated was performed by RT-qPCR
as described above. Cytotoxicity was determined using
the CellTiter-Glo luminescent cell viability assay (Promega).
White with clear bottom 384 well plates were seeded with
2x103 A549-Ace2 cells per well. The following day, indi-
vidual compounds were added using the Echo 550 acoustic
dispenser at concentrations indicated. DMSO-only (0.5%)
and camptothecin (10 µM; Sigma Aldrich) controls were
added in each plate. After 72 h incubation, 20µl/well of
Celltiter-Glo reagent was added, incubated for 20 min and the
luminescence was recorded using a luminometer (Berthold
Technologies) with 0.5 sec integration time. Curve fits and
IC50/CC50 values were obtained in Matlab.
Data availability. All mass spectrometry data, database
FASTA files, and the matlab scripts used to generate the
data in this manuscript can be found on the ProteomeX-
change Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE repository (50),
and on GitHub respectively. Specifically the proteomics
datasets have been deposited as described in table S6, where
reviewer usernames and passwords are provided.
The Matlab scripts used to process the mass spectrometry
data and produce the figures in this manuscript have been
tested in Matlab versions R2019b with the Statistics Ma-
chine Learning Toolbox, on Mac OS Catalina. These can be
accessed through the Emmott Lab Github page at: https:
//github.com/emmottlab/sars2nterm/.
Other reagent and oligo sequence details are described in ta-
ble S7.
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Table S1. Viral neo-N-termini identified from SARS-CoV-2-infected A549-Ace2 cells - .csv
Table S2. Viral neo-N-termini identified from SARS-CoV-2-infected Vero E6 cells - .csv
Table S3. All Viral peptides identified accross enriched and unenriched A549-Ace2 and Vero E6 datasets - .csv
Table S4. Quantification data for all N- and neo-N-termini quantified from SARS-CoV-2 infected A549-Ace2 cells - .csv
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Table S5. Quantification data for all N- and neo-N-termini quantified from SARS-CoV-2 infected Vero E6 cells - .csv
Dataset: PRIDE accession: Reviewer Username: Reviewer Password:
A549-Ace2 Unenriched PXD021145 reviewer34884@ebi.ac.uk ZKTFOUZA
A549-Ace2 Enriched PXD021152 reviewer62064@ebi.ac.uk xBgebTgO
A549-Ace2 Enriched (Variable Search) PXD021402 reviewer_pxd021402@ebi.ac.uk iSbBtAdt
Vero E6 Unenriched PXD021154 reviewer98284@ebi.ac.uk x3fU4szp
Vero E6 Enriched PXD021153 reviewer53878@ebi.ac.uk BiDiQ0VG
Vero E6 Enriched (Variable Search) PXD021403 reviewer_pxd021403@ebi.ac.uk x7ZdiAt6
Table S6. Proteomic datasets and access details
Table S7. Oligo sequences and reagent details - .csv
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Fig. S1. Quality control of the proteomic datasets, both pre- and post-enrichment for N-termini. A-D) Principal component analysis separates infected from mock cells and
shows reproducible clustering of biological replicates. E) Enrichment results in a majority of peptide identifications belonging to blocked N-termini, with blocked N-termini
most abundant in both F) A549-Ace2 and G) Vero E6 cells. In both cell lines, TMTpro-labelled N-termini are the most abundant enriched N-termini H), I). J) over 2700
TMTpro-labelled N-termini were identified from each dataset.
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Fig. S2. Viral N-termini and neo-N-termini identified from the viral M, ORF7A/ORF7A iORF1, ORF8, ORF9B and pp1ab replicase. Please note that ORF7A iORF1 is an
N-terminally truncated form of ORF7A that initiates at isoleucine 3 in the ORF7A sequence. The indicated neo-N-terminus beginning at amino acid 14, would therefore be
amino acid 16 in ORF7A.
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Fig. S3. Cell viability of siRNA-treated A549-Ace2 cells. Cell viability was assessed by alamarBlueAlamar blue staining and compared to untreated control cells, and a 20%










































































Fig. S4. mRNA knockdown efficiency for SARS-CoV-2 protease substrates in siRNA-treated A549-Ace2 cells. Knockdown efficiency was calculated by qRT-PCR compared
to a untreated control by the 2−∆∆Ct method. Error bars represent standard deviation from a minimum of 3 biological replicates.
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Fig. S5. Additional Inhibitors targeting SRC kinase reduce SARS-CoV-2 titres in A549-Ace2 cells. Error bars represent standard deviation from 3 biological replicates. Red
circles indicate individual datapoints.
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Fig. S6. Cell viability and CC50 calculations for inhibitor-treated A549-Ace2 cells. Cell viability was assessed by Celltiter Glo staining and compared to untreated control
cells, and a 20% ethanol-lysed control. Line represents best fit. Error bars represent standard deviation from 3 biological replicates. Black markers indicate individual data
points.
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